Your browser doesn't support javascript.
loading
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers.
Rofi, Eleonora; Del Re, Marzia; Arrigoni, Elena; Rizzo, Mimma; Fontanelli, Lorenzo; Crucitta, Stefania; Gianfilippo, Giulia; Restante, Giuliana; Fogli, Stefano; Porta, Camillo; Danesi, Romano; Schmidinger, Manuela.
Affiliation
  • Rofi E; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: eleonora0106@inwind.it.
  • Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: marzia.delre@gmail.com.
  • Arrigoni E; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: elena.arrigoni@hotmail.com.
  • Rizzo M; Department of Urology, University of Trieste, Cattinara Hospital, Trieste, Italy. Electronic address: rizzo.mimma@gmail.com.
  • Fontanelli L; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: eimi.lore@me.com.
  • Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: stefania.crucitta@gmail.com.
  • Gianfilippo G; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: g.gianfilippo10@gmail.com.
  • Restante G; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: giuliana.restante@gmail.com.
  • Fogli S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: stefano.fogli@unipi.it.
  • Porta C; Department of Internal Medicine, University of Pavia, Italy; Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy. Electronic address: camillo.porta@gmail.com.
  • Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: romano.danesi@unipi.it.
  • Schmidinger M; Unit of Medical Oncology, Department of Internal Medicine, University of Wien, Austria. Electronic address: manuela.schmidinger@meduniwien.ac.at.
Crit Rev Oncol Hematol ; 144: 102812, 2019 Dec.
Article in En | MEDLINE | ID: mdl-31698313
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Programmed Cell Death 1 Receptor / Antibodies, Monoclonal Limits: Humans Language: En Journal: Crit Rev Oncol Hematol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2019 Document type: Article Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Programmed Cell Death 1 Receptor / Antibodies, Monoclonal Limits: Humans Language: En Journal: Crit Rev Oncol Hematol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2019 Document type: Article Country of publication: Netherlands